281 results about "Peripheral blood lymphocyte" patented technology

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and / or experimental purpose.

The present invention uses peripheral blood monocyte-lymphocyte for the early diagnosis of pancreatic cancer, as well as other conditions of the pancreas and other organs. The peripheral blood lymphocytes recognize the new neoplasm in the pancreas, as well as disease processes in other organ systems. The evaluation of this specific recognition of the disease process by the peripheral blood monocyte-lymphocyte through gene microarray expression patterns constitute a successful method for the early detection of pancreatic cancer and other organ disease processes. This document describes the process used in this method of early diagnosis.

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are a polypeptide of the cell surface molecule; a polypeptide fragment thereof; a fusion polypeptide comprising the fragment; a pharmaceutical composition comprising any one of the above; and methods of using the compositions.

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1](wherein R1 represents a methyl group or an ethyl group, R2 represents a methyl group or an ethyl group, and R3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

The present invention provides a human antibody or an active-fragment thereof that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet aggregation independently; a cell that produces the antibody or its active-fragment; a pharmaceutical composition that comprises the antibody or its active-fragment as an active ingredient, and so on. The above-mentioned cell can be obtained for example, as follows: a peripheral-blood-lymphocyte of the human that produces an autologous antibody to GPVI is activated by in vitro immunization under specific conditions; a hybridoma with mouse myeloma cell is prepared; and then the hybridoma that produces a monoclonal antibody, which has a binding capacity to GPVI and has an activity that suppresses collagen-mediated agglutinability of the human platelet is selected.

The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.

A composition and method for cryopreserving cells in a non-toxic medium is described. The composition and method provide cells for cell therapy and other in vivo applications.

A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.

The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.

The invention relates to the method for producing antipeptide cytotoxic T lymphocytes (CTLs) by attaching a complex of a class I HLA and a peptide to antigen presenting cell(s) (APCs) present in a sample of peripheral blood lymphocytes (PBLs), optionally removing excess class I HLA / peptide complex, and incubating with proliferative cytokine. The invention further relates to a CTL obtainable by these methods and to a method of treating a subject by administering such a CTL to the subject.

Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes (PBLs) and marrow infiltrating lymphocytes (MILs), from blood and / or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and genetic modifications of expanded TILs, PBLs, and MILs to incorporate chimeric antigen receptors, genetically modified T-cell receptors, and other genetic modifications, and uses of such expanded and / or modified TILs, PBLs, and MILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

The invention provides an in vitro amplification method for efficient and highly cytotoxic natural killer (NK) cells. Novel artificial antigen presenting cells 4-1BBL-mIL-21-aAPC, such as 4-1BBL-mIL-21-K562 cells and the like, are constructed through stably expressing 4-1BB ligands (4-1BBL) and membrane immobilized interleukin 21 (mIL-21) on the surfaces of cell membranes, and by using the novel artificial antigen presenting cells as feeder cells for amplification, the NK cells are directly amplified from peripheral blood lymphocytes. Flow cytometry, cytotoxicity test and the like suggest that the amplified cells NK have high purity and strong cytotoxicity and have obvious killing effect on tumor cells.

The invention relates to a method for culturing an autologous peripheral blood lymphocyte. The method comprises the following steps: (1) separating a mononuclear cell from peripheral blood, resuspending in an X-VIVO15 serum-free culture medium to obtain cell concentration of 1*10<6> / mL, and culturing for 3 days; (2) supplementing the X-VIVO15 serum-free culture medium to 100 mL, adding IL-21*10<3> U / mL, and culturing for 1 day; (3) supplementing the X-VIVO15 serum-free culture medium to 200-240 mL, adding IL-21*10<3> U / mL, and culturing for 3 days; (4) supplementing the X-VIVO15 serum-free culture medium to 1000 mL, adding IL-21*10<3> U / mL, CTLA-4mAb100n g / mL and PD-1mAb100n g / mL; and (5) culturing for 5-7 days to prepare the autologous peripheral blood lymphocyte. The method disclosed by the invention can be used for improving the activation efficiency and amplification efficiency of an effector cell group by adding multiple monoclonal antibodies and cell factors to the X-VIVO15 serum-free culture medium, and can be used for effectively reducing the content of T regulatory cells by covering CTLA-4 and PD-1 molecules of the surfaces of all CIK cells by loading CTLA-4 and PD-1 antibodies in vitro especially, thus further enhancing the killing effect of the CIK cells on tumors.

Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are activated in vitro with pokeweed mitogen and then fused with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

The present invention relates to an improved growth method for natural killer cells (NK cells). More specifically, the present invention relates to a growth method for natural killer cells, which comprises a step of culturing natural killer cells in a medium containing anti-CD3 antibodies and interleukin proteins in the presence of peripheral blood leukocytes. The present invention provides an innovative growth method for natural killer cells, which can obtain a large amount of natural killer cells by remarkably increasing the growth rate compared with conventional growth methods for natural killer cells.

The invention specifically relates to a method for extracting immune cells from marrow, belonging to the technical field of cytobiology. The method comprises the following steps: (1) acquiring human marrow, diluting the human marrow with an alpha-MEM nutrient solution containing fetal calf serum, then carrying out centrifugation and discarding supernatant and a fat layer so as to obtain marrow cells; (2) transferring human peripheral blood into a centrifuge tube, carrying out centrifugation, sucking up blood plasma at an upper layer for subsequent usage and cells at a lower layer for separation of peripheral blood lymphocytes, and adding an alpha-MEM nutrient solution containing the blood plasma at the upper layer into the marrow cells to prepare a cell suspension; (3) adding a separating medium into another centrifuge tube, flatly spreading the cell suspension onto the separating medium, carrying out centrifugation, and sucking up albuginea-layer cells so as to obtain immune cells; and (4) adding isopyknic immune cells into an immune cell cryopreservation solution, carrying out uniform mixing and carrying out immune cell cryopreservation. The method provided by the invention can effectively improve the separation rate of the immune cells and the survival rate of the immune cells after cell cryopreservation and enhances the security of cells transfused back to a patient.

The invention relates to a method for evaluating DNA (Deoxyribose Nucleic Acid) damages of peripheral blood lymphocytes caused by ionizing radiation. The method mainly comprises the following steps: irradiating peripheral blood through ionizing radiation; marking gamma-H2AX proteins in a peripheral blood lymphocyte and a granulocyte by using specific antibodies; analyzing contents of the gamma-H2AX proteins in the two cells through the flow cytometry; by taking the granulocyte as reference, figuring out relative content of the gamma-H2AX proteins in the lymphocyte; and evaluating the DNA damage degree of the ionizing radiated peripheral blood lymphocyte by using RL / G value of the gamma-H2AX (ratio between the content of the gamma-H2AX proteins in the lymphocyte and the content of the gamma-H2AX proteins in the granulocyte). The method for evaluating the DNA damages of the peripheral blood lymphocytes caused by the ionizing radiation, provided by the invention, has the advantages of simplicity in operation and stable result and can be widely applied to the field of diagnosis, cell biology research and so on.

The invention relates to a method for culturing autologous peripheral blood lymphocytes, comprising the following steps of: (1) separating a PBMC (Peripheral Blood Mononuclear Cell) from peripheral blood, then heavily suspending in a serum-free culture medium, and statically culturing to prepare a primary culture solution; (2) replenishing the serum-free culture medium to the primary culture solution, simultaneously adding IL (Interleukin)-2, and statically culturing to prepare a secondary culture solution; (3) replenishing the serum-free culture medium to the secondary culture solution, simultaneously adding IL-2, and statically culturing to prepare a culture solution; and (4) uniformly dividing the culture solution into two parts, adding the serum-free culture medium to complement a sufficient volume, adding IL-2, statically culturing, and repeating the step (4) to prepare the autologous peripheral blood lymphocytes. As multiple monoclonal antibodies and cell factors are added to the serum-free culture medium, the activation efficiency and the amplification efficiency of effector cell masses are improved. Through detection, the activation efficiency and the amplification efficiency are obviously improved as compared with the existing method, and a large amount of cell masses occur after the effector cell masses are activated about 3 days.

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor alpha -subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

The invention relates to the method for producing antipeptide cytotoxic T lymphocytes (CTLs) by attaching a complex of a class I HLA and a peptide to antigen presenting cell(s) (APCs) present in a sample of peripheral blood lymphocytes (PBLs), optionally removing excess class I HLA / peptide complex, and incubating with proliferative cytokine. The invention further relates to a CTL obtainable by these methods and to a method of treating a subject by administering such a CTL to the subject.

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof.wherein each symbol is as defined in the specification.

The present invention relates to a cell line of lymphocytes comprising γδ T cells, composition and production method thereof, and medical use namely for the use in medicine, namely in cancer immunotherapy.The cell line comprise a sample of human peripheral blood Vδ1+γδ T cells expressing functional natural cytotoxicity receptors (NCRs). These Vδ1+ NCR+ T lymphocytes can directly mediate killing of leukemia cell lines and chronic lymphocytic leukemia patient neoplastic cells.The present invention shows that human Vδ1+ NCR+ T cells can be differentiated and expanded from total γδ peripheral blood lymphocytes (PBLs), upon regular in vitro or ex vivo stimulation with γδTCR agonists and γc-family cytokines. This subset surprisingly expresses NKp30, NKp44 and NKp46, and high levels of Granzyme B that associate with highly enhanced cytotoxicity against lymphoid leukemias.

The invention relates to a traditional Chinese medicine immunopotentiator (an astragalus polysaccharide immunopotentiator for short) prepared from astragalus extracts and sulfated epimedium polysaccharides, which belongs to the field of immunological adjuvants of livestock and poultry. 1,000ml of the liquid medicine is prepared from 40g of astragalus and 120g of epimedium herb. The preparation method of the immunopotentiator comprises the following steps of: decocting the astragalus with water for three times, then merging the obtained filter liquor and condensing the filter liquor into 500ml of astragalus solution; extracting the epimedium polysaccharides by using the epimedium herb water decoction and ethanol precipitate method, then decorating the polysaccharides by using the chlorosulfonic acid-pyridine method, and preparing the polysaccharides into 500ml of sulfated epimedium polysaccharide solution after carrying out distilled water dialysis on the polysaccharides; and mixing the astragalus solution and the sulfated epimedium polysaccharide solution, and then filtering, sub-packaging and sterilizing to obtain the traditional Chinese medicine astragalus polysaccharide immunopotentiator. The immune experiment shows that the astragalus polysaccharide immunopotentiator has the advantage of obviously improving the proliferation of peripheral blood lymphocyte of chicken and enhancing the cellular immunity, obviously improving the potency of a serum antibody, promoting the lymphocyte proliferation, enhancing the cellular immunity and humoral immunity, and improving the immune response of a vaccine by coordinately immunizing chickling by using the Newcastle disease vaccine.

The invention relates to a human peripheral blood lymphocytes culture medium and the application thereof. The human peripheral blood lymphocytes culture medium of the invention comprises: RPMI1640 liquid culture medium 77-81.9%, bovine blood 10-14.9%, PHA 4-9%, non-sulfated glycosaminoglycan 2-5%, CPPs 2-5% and Double-resist 0.05-0.1%. The culture medium provided in the invention achieves a high lymphocyte conversion rate, a high lymphocyte split index and a good reagent stability; can obtain a human chromosome figure which can provide a firm basis to chromosome core type analysis and clinic diagnosis.

The invention discloses a preparation method for pork lung protein peptide, which adopts waste liquid after the heparin sodium extraction from pork lungs as raw materials and comprises the steps of desalting, enzymolysis, ultrafiltration membrane separation and drying. The invention also discloses the pork lung protein peptide obtained by the method and an application of the pork lung protein peptide, which solve the problems of biological resource waste, environment pollution and the like of the waste liquid after the heparin sodium extraction from the pork lungs, in addition, the utilization value of products is greatly improved through the continuous processing process, the prepared pork lung protein peptide is easy to absorb and has special biological activity, the animal yield can be improved when the pork lung protein peptide is applied to high-grade feedstuff, and the pork lung protein peptide can also be used for preparing compounds for improving the immunity or can be used for preparing compounds for enhancing peripheral blood lymphocytes.